CRISPR Therapeutics CRSP is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 2.5% at $56.46. The stock's performance was behind the S&P 500's daily gain of 0.46%. On the other hand, the Dow registered a gain ...